1. Home
  2. YMAT vs APVO Comparison

YMAT vs APVO Comparison

Compare YMAT & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YMAT

J-Star Holding Co. Ltd. Ordinary Shares

HOLD

Current Price

$1.49

Market Cap

9.9M

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$4.86

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YMAT
APVO
Founded
1970
2016
Country
Taiwan
United States
Employees
65
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9M
8.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
YMAT
APVO
Price
$1.49
$4.86
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.0M
26.3K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.13
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.50
52 Week High
$6.45
$13.11

Technical Indicators

Market Signals
Indicator
YMAT
APVO
Relative Strength Index (RSI) 60.64 50.82
Support Level $0.41 $4.29
Resistance Level $2.26 $5.66
Average True Range (ATR) 0.54 0.33
MACD 0.03 0.02
Stochastic Oscillator 42.89 65.17

Price Performance

Historical Comparison
YMAT
APVO

About YMAT J-Star Holding Co. Ltd. Ordinary Shares

J-Star Holding Co Ltd is engaged in the research, development, and manufacturing of carbon fiber for a wide variety-of-products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products. The company has five segments: Bicycle frame, Racket, Crank, Service provision, and Others. The majority of its revenue is generated from the Bicycle frame segment. Geographically, the company operates in Taiwan, China, and other regions.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: